Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy

American Journal of Tropical Medicine and Hygiene

Volumn 70, Issue 2, 2004, Pages 197-200

  Villahermosa, Laarni G ^a   Fajardo Jr , Tranquilino T ^a   Abalos, Rodolfo M ^a   Cellona, Roland V ^a   Balagon, Maria V ^a   Dela Cruz, Eduardo C ^a   Tan, Esterlina V ^a   Walsh, Gerald P ^c   Walsh, Douglas S ^b  

^a Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^b EISENHOWER ARMY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; MINOCYCLINE; OFLOXACIN; PREDNISOLONE; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL ASSESSMENT; MULTIBACILLARY LEPROSY; NEUROPATHY; PATIENT COMPLIANCE; RELAPSE; SIDE EFFECT; SKIN PIGMENTATION; TREATMENT OUTCOME; ULNAR NERVE; WORLD HEALTH ORGANIZATION;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); UNCULTURED ACTINOMYCETE;

EID: 1042265240     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.70.197     Document Type: Article

References (30)

1. WHO Study Group, 1982. Chemotherapy of Leprosy for Control Programmes. World Health Organ Tech Rep Ser.
2. Grosset JH, 2001. Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 69: S14-S18.
3. WHO Expert Committee on Leprosy, Seventh Report, 1998. World Health Organ Tech Rep Ser 874.
4. Ji B, 1998. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr Rev 69: 106-109.
5. Lockwood DN, 2002. Leprosy elimination-a virtual phenomenon or a reality? BMJ 324: 1516-1518.
6. 1997. Leprosy beyond the year 2000 (editorial). Lancet 350: 1717.
7. Suneetha S, Reddy R, 2001. Histological resolution and bacterial clearance with pulse ROM therapy in borderline lepromatous leprosy. Int J Lepr Other Mycobact Dis 69: 53-54.
8. Villahermosa LG, Walsh DS, Fajardo TT Jr, Abalos RM, dela Cruz EC, Veerasubramanian P, Walsh GP, 1999. Resolution of lepromatous leprosy after a short course of amoxicillin/clavulanic acid, followed by ofloxacin and clofazimine. Int J Dermatol 38: 558-560.
9. Fajardo TT, Abalos RM, dela Cruz EC, Villahermosa LG, Walsh DS, Cellona RV, Balagon MV, Tan EV, Walsh GP, 1999. Clofazimine therapy for lepromatous leprosy: a historical perspective. Int J Dermatol 38: 70-74.
10. Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J, 1998. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother 42: 1115-1120.
11. Gupte MD, 2000. Field trials of a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy. Lepr Rev 71 (Suppl): S77-S80.
12. WHO, 1997. MDT, Questions and Answers. World Health Organ Tech Rep Ser, 26-27.
13. World Health Organization, 1998. Model Prescribing Information: WHO Drugs Used in Leprosy. Geneva: World Health Organization, 12-14.
14. Mane I, Cartel JL, Grosset JH, 1997. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Int J Lepr Other Mycobact Dis 65: 224-229.
15. Ji B, Jamet P, Sow S, Perani EG, Traore I, Grosset JH, 1997. High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother 41: 1953-1956.
16. Baohong J, 2001. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev 72: 3-7.
17. Ridley DS, 1964. Bacterial indices. Cochrane RG, Davey TF, eds. Leprosy in Theory and Practice. Baltimore: Williams and Wilkins, 620-624.
18. Sehgal VN, Joginder, 1990. Slit-skin smear in leprosy. Int J Dermatol 29: 9-16.
19. Ridley DS, Jopling WH, 1966. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34: 255-273.
20. Ridley DS, Hilson GRF, 1967. A logarithmic index of bacilli in biopsies: I. method; II. evaluation. Int J Lepr Other Mycobact Dis 35: 184-192.
21. Pattyn S, Grillone S, 2002. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev 73: 245-247.
22. Ji B, 2001. Does dapsone resistance really matter in the MDT era? Int J Lepr Other Mycobact Dis 69: 54-55.
23. Rao PN, Lakshmi TS, 2001. Increase in the incidence of dapsone hypersensitivity syndrome-an appraisal. Lepr Rev 72: 57-62.
24. Reeve PA, Ala J, Hall JJ, 1992. Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy. J Trop Med Hyg 95: 266-270.
25. Griffiths S, Ready N, 2001. Defaulting patterns in a provincial leprosy control programme in northern Mozambique. Lepr Rev 72: 199-205.
26. Chen XS, Ye GY, Jiang C, Li WZ, Bian J, Wang H, Chen W, 1997. An investigation of attitudes, beliefs and behaviour of leprosy patients, family members and PHC workers towards multidrug therapy in Yangzhou and Dongtai Districts of China. Lepr Rev 68: 155-161.
27. Blok LM, Bloos LJ, van den Berg G, 1991. A retrospective study on seven years of multiple drug treatment for paucibacillary and multibacillary leprosy, in Bayara General Hospital, Nigeria. Lepr Rev 62: 193-200.
28. Grosset JH, Cole ST, 2001. Genomics and the chemotherapy of leprosy. Lepr Rev 72: 429-440.
29. Gelber RH, 1994. Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Eur J Clin Microbiol Infect Dis 13: 942-952.
30. Rao PS, Ramachandran A, Sekar B, Ravi S, Subramanian M, 1994. Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy. Lepr Rev 65: 181-189.